ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy of Intraoperative Injections on Postoperative Pain Control During Total Hip Replacement

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03119038
Recruitment Status : Terminated (Investigator no longer actively pursuing this study.)
First Posted : April 18, 2017
Last Update Posted : May 16, 2018
Sponsor:
Information provided by (Responsible Party):
Brett Levine, MD, Rush University Medical Center

Brief Summary:
The purpose of this study is to clarify the efficacy of a multidrug versus single drug periarticular injection when only standard operative and postoperative pain management protocols used and the control group is exposed to what our investigators believe is the standard of care, single medication periarticular injection

Condition or disease Intervention/treatment Phase
Osteoarthritis Degenerative Joint Disease Drug: Bupivicaine + epinephrine Drug: Bupivacaine Drug: Ropivacaine Drug: Ketorolac Drug: Clonidine Injection Phase 4

Detailed Description:

Study Objectives The intraoperative periarticular injection of 300 mg of 0.5% ropivacaine, 30 mg ketorolac, 200 mcg epinephrine, and 100 mcg clonidine in a 100 mL 0.9% saline solution will be compared to an injection of 30 mL of a 0.25% solution bupivacaine with ORA: 15101602-IRB01 Date IRB Approved: 3/16/2016 epinephrine and 30 mL 0.25% bupivacaine without epinephrine as an intraoperative periarticular joint injection protocol. The study's data collection timeline begins at the pre-operative clinic visit. Data collection continues through the patient's discharge after the surgical procedure and until the first year postoperative visit examination of joint range of motion and patient satisfaction questionnaires.

Primary Objectives:

The primary objective is to evaluate the efficacy of a multidrug versus bupivacaine intraoperative injection in decreasing total hip arthroplasty postoperative pain. To determine this, postoperative analgesic consumption will be collected for each patient and the value when converted to morphine equivalents will be compared between cohorts.

Analysis of morphine equivalent values at various postoperative time intervals (0-6 hours, 6-12 hours, 12-18, 18-24, then each postoperative day) and total morphine equivalent consumption for the entire length of stay will be performed between treatment cohorts.

Secondary Objectives:

To establish the improvement in postoperative pain relief provided by intraoperative periarticular injection of our multidrug protocol versus bupivacaine, other data points will be collected. The physical therapy milestones including time to first get out of bed, time to ambulation with or without assistance, time to climb stairs, and time to active straight leg raise will all be collected. The zero time point will be the end of the operation. Pain scale scores during physical therapy sessions with physiotherapists will also be recorded.

Resting visual analog scores for pain assessment will be collected as the patient representing their pain on a scale from 0 to 100 mm. The VAS values will be collected at various postoperative time values until discharge. The length of hospital stay will be collected as well. Opioid side effects will also be collected including over sedation, respiratory depression, urinary retention, and constipation. Other data collected will include operation time, wound complications, intraoperative blood loss, and postoperative drain output. At the 6 weeks postoperative visit, patient satisfaction questionnaires will be collected compared to preoperative visit values.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 6 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Efficacy of Intraoperative Injections on Postoperative Pain Control During Total Hip Arthroplasty: A Prospective, Blinded, Randomized Controlled Study
Actual Study Start Date : April 2016
Actual Primary Completion Date : April 30, 2018
Actual Study Completion Date : April 30, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Combination Medication Injection
Intraoperative periarticular injection of 300 mg of 0.5% ropivacaine, 30 mg ketorolac, 200 mcg epinephrine, and 100 mcg clonidine in a 100 mL 0.9% saline solution
Drug: Ropivacaine
Intraoperative periarticular injection of 300 mg of 0.5% ropivacaine

Drug: Ketorolac
Intraoperative periarticular injection of 30 mg

Drug: Clonidine Injection
Intraoperative periarticular injection of 100 mcg clonidine in a 100 mL 0.9% saline solution

Active Comparator: Single Medication Injection
Intraoperative periarticular injection of 30 mL of a 0.25% solution bupivacaine with epinephrine and 30 mL 0.25% bupivacaine without epinephrine
Drug: Bupivicaine + epinephrine
Intraoperative periarticular injection of 30 mL of a 0.25% solution bupivacaine with epinephrine

Drug: Bupivacaine
Intraoperative periarticular injection of 30 mL of a 0.25% solution bupivacaine without epinephrine




Primary Outcome Measures :
  1. Record narcotic usage, in morphine equivalents, during postoperative inpatient hospital stay. [ Time Frame: From date of randomization until the date of hospital discharge or the date of 10 days after surgery, whichever date comes first ]
    Narcotic usage


Secondary Outcome Measures :
  1. Record time to achieve physical therapy milestones during inpatient physical therapy [ Time Frame: From date of randomization until the date of hospital discharge or the date of 10 days after surgery, whichever date comes first ]
    Time to achieve physical therapy milestones

  2. Record VAS values during postoperative period [ Time Frame: From date of randomization until the date of hospital discharge or the date of 10 days after surgery, whichever date comes first ]
    VAS values

  3. Length of hospital stay [ Time Frame: From date of randomization until the date of hospital discharge or the date of 10 days after surgery, whichever date comes first ]
    Length of stay



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Patients must be male or female of any race
  2. Ages 18-80 years old
  3. Patients must have a primary hip arthroplasty by principal investigator or co-investigator

Exclusion Criteria

  1. Allergy or intolerance to the study materials
  2. Surgical intervention during the past month for the treatment of the painful joint or its underlying etiology
  3. History of previous surgeries on the affected joint other ORA: 15101602-IRB01 Date IRB Approved: 3/16/2016 than arthroscopy (open surgeries)
  4. History of or current substance abuse or addiction
  5. History of or current psychiatric diagnosis
  6. Failure in collecting a required data point during study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03119038


Locations
United States, Illinois
Rush University Medical Center
Chicago, Illinois, United States, 60612
Sponsors and Collaborators
Rush University Medical Center

Responsible Party: Brett Levine, MD, Associate Professor, Rush University Medical Center
ClinicalTrials.gov Identifier: NCT03119038     History of Changes
Other Study ID Numbers: ORA-15101602
First Posted: April 18, 2017    Key Record Dates
Last Update Posted: May 16, 2018
Last Verified: May 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Brett Levine, MD, Rush University Medical Center:
total hip
degenerative joint disease
osteoarthritis

Additional relevant MeSH terms:
Osteoarthritis
Pain, Postoperative
Joint Diseases
Arthritis
Musculoskeletal Diseases
Rheumatic Diseases
Pain
Neurologic Manifestations
Nervous System Diseases
Postoperative Complications
Pathologic Processes
Signs and Symptoms
Pharmaceutical Solutions
Bupivacaine
Ropivacaine
Epinephrine
Racepinephrine
Epinephryl borate
Ketorolac
Ketorolac Tromethamine
Clonidine
Anesthetics, Local
Anesthetics
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents